Skip to content
DataLookout
Menu

NCT07919470

Busulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCT

StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

1-Year Leukemia-Free Survival (LFS)
Timeframe: 12 months post-hematopoietic stem-cell infusion]

Secondary (7)

1-Year Treatment-Related Mortality (TRM)
Cumulative Incidence of Relapse (CIR)
Cumulative Incidence of Acute and Chronic Graft-Versus-Host Disease (GVHD)
Overall Survival (OS)
Conditioning-related organ toxicities
Show 2 moreShow less
Hematopoietic engraftment
Molecular/Flow-MRD status post-transplant

Arms and interventions

Chemotherapy-only Conditioning RegimenExperimental

intervention: Drug: Busulfan: 0.8 mg/kg intravenous, four times daily, day -8 to day -6 Drug: Cyclophosphamide: 1.8 g/m²/day intravenous, day -5, day -4 Drug: Semustine: 250 mg/m² oral, day -3 Drug: Rabbit anti-thymocyte globulin (ATG): 2.5 mg/kg/day intravenous day -5 to -2 (only for haploidentical transplant recipients) All subjects receive identical post-transplant GVHD-prophylaxis: cyclosporine-A, mycophenolate mofetil, short-course methotrexate; standard supportive care.

TBI-based Conditioning RegimenActive comparator

intervention Radiation: Total-Body Irradiation (TBI): 770 cGy administered on day -6 Drug: Cyclophosphamide: 1.8 g/m²/day intravenous, day -5, day -4 Drug: Semustine: 250 mg/m² oral, day -3 Drug: Rabbit anti-thymocyte globulin (ATG): 2.5 mg/kg/day intravenous day -5 to -2 (only for haploidentical transplant recipients) All subjects receive identical post-transplant GVHD-prophylaxis: cyclosporine-A, mycophenolate mofetil, short-course methotrexate; standard supportive care.

Drugs: Chemotherapy-based Conditioning Regimen

Radiation: TBI-based conditioning

Sites

1 site in 1 country

  • Peking University People's Hospital, Beijing Lu Daopei Hematology Hospital, Hebei Yanda Lu Daopei Hospital, Nanfang Hospital, Southern Medical UniversityBeijing, China